Alitair Pharmaceuticals has gained a notice of allowance from the US Patent and Trademark Office for its ion exchange resin platform drug delivery technology, REA. Alitair has out-licensed two product candidates utilizing its REA platform ...
Tags: Alitair Pharmaceuticals, REA Drug Delivery Technology, US Patent